Neurogene (NGNE)

Cash burn rate (est.)	Burn method: Change in cash		Burn method: Operating income		Burn method: FCF (opex + capex)
	Last Q	Avg 4Q	Last Q	Avg 4Q	Last Q	Avg 4Q
Cash on hand (at last report)	66.97 mm	66.97 mm	66.97 mm	66.97 mm	66.97 mm	66.97 mm
Cash burn (monthly)	14.80 mm	(no burn)	7.39 mm	6.32 mm	5.19 mm	5.84 mm
Cash used (since last report)	75.21 mm	n/a	37.57 mm	32.11 mm	26.36 mm	29.68 mm
Cash remaining	-8.23 mm	n/a	29.40 mm	34.86 mm	40.61 mm	37.30 mm
Runway (months of cash)	-0.6	n/a	4.0	5.5	7.8	6.4

Beta Read what these cash burn values mean

Financial data from Neurogene earnings reports.

Institutional ownership, Q4 2024

NGNE institutional ownership history Ownership history

84.9% owned by funds/institutions

13F holders	Current	Prev Q	Change
Total holders	90	87	+3.4%
Opened positions	28	23	+21.7%
Closed positions	25	3	+733.3%
Increased positions	31	22	+40.9%
Reduced positions	17	22	-22.7%

13F shares	Current	Prev Q	Change
Total value	364.05 bn	580.17 bn	-37.3%
Total shares	17.81 mm	15.13 mm	+17.7%
Total puts	241.20 k	0.00	NEW
Total calls	103.20 k	0.00	NEW
Total put/call ratio	2.3	–	–

Largest owners	Shares	Value	Change
Samsara BioCapital	1.72 mm	$44.30 mm	+33.9%
Samsara BioCapital	1.72 mm	$39.25 bn	+35.4%
BlackRock	1.52 mm	$34.66 bn	+10.5%
RTW Investments	1.35 mm	$30.87 bn	+18.9%
Redmile	1.32 mm	$30.17 bn	+36.9%
Casdin Capital	1.30 mm	$29.61 bn	+146.9%
EcoR1 Capital	1.27 mm	$29.06 bn	0.0%
FMR	860.33 k	$19.67 bn	+17.6%
Commodore Capital	800.00 k	$18.29 bn	+300.0%
Baker Bros. Advisors	674.45 k	$15.42 bn	+47.9%

Largest transactions	Shares	Bought/sold	Change
Casdin Capital	1.30 mm	+770.75 k	+146.9%
JHG Janus Henderson	0.00	-709.47 k	EXIT
Commodore Capital	800.00 k	+600.00 k	+300.0%
Great Point Partners	442.76 k	-561.53 k	-55.9%
JPM JPMorgan Chase & Co.	481.00 k	+476.42 k	+10395.3%
Samsara BioCapital	1.72 mm	+449.34 k	+35.4%
Deerfield Management	448.15 k	+448.15 k	NEW
Samsara BioCapital	1.72 mm	+434.56 k	+33.9%
Avidity Partners Management	0.00	-425.04 k	EXIT
Redmile	1.32 mm	+355.42 k	+36.9%

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

Recent insider trades

NGNE insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value	#Remaining
26 Nov 24	Samsara BioCapital GP	Common Stock	Buy	Acquire P	Yes	No	27.5	2,000	55.00 k	1,717,127
26 Nov 24	Samsara BioCapital GP	Common Stock	Buy	Acquire P	Yes	No	26.73	15,219	406.80 k	1,715,127
26 Nov 24	Samsara BioCapital GP	Common Stock	Buy	Acquire P	Yes	No	26.01	10,803	280.99 k	1,699,908
26 Nov 24	Samsara BioCapital GP	Common Stock	Buy	Acquire P	Yes	No	24.91	20,748	516.83 k	1,689,105
22 Nov 24	Christine Mikail Cvijic	Common Stock	Buy	Acquire P	No	No	20.475	24,000	491.40 k	76,844
22 Nov 24	Rachel McMinn	Common Stock	Buy	Acquire P	No	No	20.4	47,500	969.00 k	1,297,859
14 Jun 24	Noonberg Sarah B.	Stock Option Common Stock	Grant	Acquire A	No	No	42.59	7,700	327.94 k	7,700

Data from 3, 4 and 5 filings. Values as filed, not updated for current price.

Press releases

From Benzinga Pro

Neurogene to Participate in Upcoming Conferences

24 Feb 25

Neurogene Inc. (NASDAQ:NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that Company management will

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Neurogene Inc. - NGNE

4 Feb 25

NEW YORK, Feb. 4, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Neurogene Inc. ("Neurogene" or the "Company") (NASDAQ:NGNE). Such investors are advised to contact

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Neurogene Inc. - NGNE

28 Jan 25

NEW YORK, Jan. 28, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Neurogene Inc. ("Neurogene" or the "Company") (NASDAQ:NGNE). Such investors are advised to contact

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Neurogene Inc. - NGNE

21 Jan 25

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Neurogene Inc. - NGNE

8 Jan 25